Introduction {#sec1}
============

The spontaneous rupture of hepatocellular carcinoma (HCC) is a rare but life-threatening presentation of this disease and cause of death in 6.4% of such cases in Japan \[[@cit0001]\]. The affected patients frequently have poor liver function due to liver cirrhosis and advanced tumour stage, and previous reports showed that the one-month mortality rate ranged from 28% to 71% with a median survival period of 4 to 32 weeks \[[@cit0002]-[@cit0008]\]. The spontaneous rupture of HCC has been treated with several different methods such as conservative treatment (Cons T) and transcatheter arterial embolisation (TAE). However, due to its relative rarity and difficulty in conducting prospective comparisons, there is little consensus on the appropriate management and prognostic factors. Therefore, we introduced a multi-centre retrospective study to elucidate the prognostic factors in the spontaneous rupture of HCC and to determine whether TAE is associated with better prognosis than Cons T.

Material and methods {#sec2}
====================

Study population and clinical data {#sec2.1}
----------------------------------

This multicentre retrospective study was approved by the Institutional Review Board of each participating institution, and the need for informed consent acquisition was waived.

We retrospectively analysed pooled data obtained from the clinical and radiological records of 71 consecutive patients (56 males and 15 females; age range 32-86 years, mean 65.1 years) with spontaneous rupture of HCC, who were treated between October 1989 and December 2011 in three different sites in two countries: hospital A (15 patients), B (43 patients), and C (13 patients). Cause of liver damage (hepatitis type), Child-Pugh classification (A, B, or C), presence/absence of hepatic encephalopathy, ascites, shock vital (systolic blood pressure \< 80 mmHg), portal vein tumour thrombosis, distant metastasis, and past history of HCC treatment, tumour size (maximum diameter on axial CT image), tumour morphology (massive or diffuse), serum α-fetoprotein (AFP), blood chemistry data (serum albumin, total bilirubin, aspartate aminotransferase \[AST\], alanine transaminase \[ALT\], blood urea nitrogen \[BUN\], and creatinine), haemoglobin, prothrombin time, primary management (TAE or conservative), and secondary management (TAE or surgery or none) were recorded.

Treatment methods {#sec2.2}
-----------------

Attending physician assessed patients' states and conducted the treatment method (TAE or Cons T) and obtained consent from the patient or patient's family. TAE was approached from femoral artery with the Seldinger technique. Angiographic catheter was inserted in the hepatic artery and contrast agent was injected, so that branches of bleeding hepatic artery were identified. As an embolic material, gelatin sponge that was cut into small cubes of approximately 1-2 mm^3^ in size was injected into bleeding arteries. The embolic procedure was finished because we could confirm the stopping of bleeding by angiography. In conservative treatment, a haemostatic agent and/or pain relief drug was intravenously infused.

Statistical analyses {#sec2.3}
--------------------

The χ^2^ test for independence or the Fisher exact test was used for comparison of the two groups. To determine factors influencing overall survival, a univariate analysis was performed using the Kaplan-Meier method and a log-rank test. The survival period was defined as the length of time from the onset of the spontaneous rupture of HCC until death. Subsequently, to identify independent prognostic factors, multivariable analysis was performed using the Cox proportional hazard model from which hazard ratios with their confidence intervals and *p* values were reported. *P* \< 0.05 was considered statically significant for all analyses. All statistical analyses were performed using StatView; SAS software.

Results {#sec3}
=======

The patients' characteristics are shown in [Table 1](#t0001){ref-type="table"}. Cause of liver damage was alcoholic in seven patients (10%), hepatitis B in 28 patients (39%), hepatitis C in 18 patients (25%), and non-B non-C in six patients (8%). Eight patients (11%) were in Child-Pugh A class, 34 (48%) in B class, and 22 (31%) in C class. Five patients (7%) had hepatic encephalopathy. Fifty-nine patients (83%) had ascites. Ten patients (16%) had shock vital at the time of admission. Mean tumour size of HCCs was 7.5 cm. Forty-two patients (59%) had past history of HCC treatment. Mean follow-up period was 106.8 days (range 0-2972 days).

###### 

Patient characteristics of the analysed cohort and comparisons between conservative treatment group (Cons T) and transcatheter arterial embolisation (TAE) groups

  Variables                                Total            Cons T group    TAE group        *p* value
  ---------------------------------------- ---------------- --------------- ---------------- -----------
  Patients, *n* (%)                        71               20 (28)         51 (72)          
  Age (y)                                  65.1 (13.3)      68.2 (10.7)     63.8 (14.1)      0.378 NS
  Sex, *n* (%)                             0.621 NS                                          
   Male                                    56 (79)          15 (75)         41 (80)          
   Female                                  15 (21)          5 (25)          10 (20)          
  Cause of liver damage, *n* (%)           0.767 NS                                          
   Alcohol                                 7 (10)           1 (5)           6 (12)           
   Hepatitis B                             28 (39)          7 (35)          21 (41)          
   Hepatitis C                             18 (25)          4 (20)          14 (27)          
   Non-B, non-C                            6 (8)            1 (5)           5 (10)           
  Child-Pugh classification, *n* (%)       0.786 NS                                          
   A                                       8 (11)           2 (10)          6 (12)           
   B                                       34 (48)          8 (40)          26 (51)          
   C                                       22 (31)          7 (35)          15 (29)          
  Hepatic encephalopathy, *n* (%)          0.002                                             
   Present                                 5 (7)            4 (20)          1 (2)            
  Ascites, *n* (%)                                                                           0.209 NS
   Present                                 59 (83)          15 (75)         44 (86)          
  Shock vital, *n* (%)                     0.719 NS                                          
   Present                                 16 (22)          4 (20)          12 (23)          
  Tumour size (cm)                         7.5 (3.9)        7.2 (0.8)       7.6 (4.1)        0.842 NS
  Tumour morphology, *n* (%)               0.778 NS                                          
   Massive                                 34 (47)          6 (30)          28 (54)          
    Diffuse                                14 (19)          5 (25)          9 (17)           
  Portal vein tumour thrombosis, *n* (%)   0.326 NS                                          
    Present                                19 (27)          7 (35)          12 (24)          
  History of HCC treatment, *n* (%)        0.089 NS                                          
   Present                                 42 (59)          15 (75)         27 (53)          
  Secondary management, *n* (%)            0.083 NS                                          
    TAE                                    6 (8)            0 (0)           6 (12)           
    Surgery                                1 (1)            1 (5)           0 (0)            
    None                                   62 (87)          19 (95)         43 (84)          
  Serum albumin (g/l)                      2.85 (0.64)      2.81 (0.55)     2.87 (0.68)      0.720 NS
  Serum total bilirubin (µmol/l)           3.47 (5.08)      5.89 (8.62)     2.51 (2.39)      0.012
  Serum AFP (ng/ml)                        47821 (113213)   7721 (14084)    58132 (125013)   0.238 NS
  AST (U/l)                                197.8 (262.5)    205.0 (218.9)   195.0 (278.9)    0.889 NS
  ALT (U/l)                                114.7 (240.7)    96.6 (118.5)    121.4 (273.4)    0.705 NS
  Haemoglobin (g/dl)                       8.99 (2.49)      9.16 (2.53)     8.92 (2.50)      0.726 NS
  Prothrombin time (s)                     32.8 (24.6)      18.7 (15.1)     37.8 (25.0)      0.003
  BUN (mg/dl)                              24.2 (15.7)      26.8 (20.4)     23.3 (13.7)      0.411 NS
  CRE (mg/dl)                              1.43 (1.47)      1.23 (0.79)     1.50 (1.65)      0.524 NS

Cons T -- conservative treatment, TAE -- transcatheter arterial embolization, NS -- not significant, AFP -- α-fetoprotein, AST -- aspartate aminotransferase, ALT -- alanine aminotransferase

Continuous variables are indicated in the mean (SD)

Conservative treatment (Cons T group) was employed as the primary management in 20 patients (28%), while transcatheter arterial embolisation (TAE group) was performed in the remaining 51 patients (72%). Hepatic encephalopathy was more frequent in the Cons T group than in the TAE group (*p* = 0.001). In addition, serum total bilirubin was significantly higher (*p* = 0.012) and prothrombin time was significantly shorter (*p* = 0.003) in the Cons T group than in the TAE group. No significant difference was found in the other variables between the two groups.

The median survival time (MST) was 22 days, and one-month mortality rate was 56% in all patients. MST in the Cons T group was 16 days and the survival rate was poor: 75 % at seven days, 60 % at 14 days, 39 % at one month, and 22% at three months. On the other hand, MST in TAE group was 28 days and the survival rate was 83% at seven days, 73% at 14 days, 63% at one month, 27% at three months, 18% at 12 months, and 18% at 24 months. However, there was no statistically significant difference in the survival rate between the Cons T and TAE groups (*p* = 0.213) ([Table 2](#t0002){ref-type="table"}, [Figure 1](#f0001){ref-type="fig"}). Factors associated with significantly lower overall survival included being female (*p* = 0.006), higher Child-Pugh grade (*p* = 0.012), presence of hepatic encephalopathy (*p* \< 0.001), presence of portal vein tumor thrombosis (*p* \< 0.001), presence of distant metastasis (*p* = 0.005), presence of past history of HCC (*p* = 0.049), lower serum albumin (*p* = 0.018), higher total bilirubin (*p* \< 0.001), and longer prothrombin time (*p* = 0.017) ([Table 2](#t0002){ref-type="table"}).

###### 

Univariate analysis searching for factors influencing overall survival

  Variables                        Number   Median survival (day)   *p* value (log-rank)
  -------------------------------- -------- ----------------------- ----------------------
  Age                                                               0.316 NS
   ≤ 58                            24       17                      
   \> 58 and \< 73                 22       25                      
   ≥ 73                            25       20                      
  Sex                                                               0.006
   Male                            56       25                      
   Female                          15       10                      
  Institution                                                       0.855 NS
   A                               15       20                      
   B                               43       17                      
   C                               13       28                      
  Primary management                                                0.213 NS
   TAE                             51       28                      
   Cons T                          20       16                      
  Child-Pugh classification                                         0.012
   A                               8        30                      
   B                               34       22                      
   C                               22       11                      
  Hepatic encephalopathy                                            \< 0.001
   Absent                          64       25                      
   Present                         5        1                       
  Ascites                                                           0.988 NS
   Absent                          11       17                      
   Present                         59       22                      
  Shock vital                                                       0.105 NS
   Absent                          54       28                      
   Present                         16       10                      
  Tumour size (cm)                                                  0.832 NS
   ≤ 4.3                           17       29                      
   \> 4.3 and \< 7.8               18       25                      
   ≥ 7.8                           19       11                      
  Tumour morphology                                                 0.748 NS
   Massive                         34       22                      
   Diffuse                         14       16                      
  Portal vein tumour thrombosis                                     \< 0.001
   Absent                          52       29                      
   Present                         19       10                      
  Distant metastasis                                                0.005
   Absent                          55       25                      
   Present                         16       14                      
  History of HCC treatment                                          0.049
   Absent                          29       18                      
   Present                         42       28                      
  Serum albumin (g/l)                                               0.018
   ≤ 2.5                           23       11                      
   \> 2.5 and \< 3.2               21       38                      
   ≥ 3.2                           20       20                      
  Serum total bilirubin (µmol/l)                                    \< 0.001
   ≤ 1.2                           23       34                      
   \> 1.2 and \< 2.5               23       20                      
   ≥ 2.5                           24       10                      
  Serum AFP (ng/ml)                                                 0.173 NS
   ≤ 420                           14       30                      
   \> 420 and \< 15 700            15       15                      
   ≥ 15 700                        15       18                      
  AST (U/l)                                                         0.079 NS
   ≤ 63                            23       28                      
   \> 63 and \< 144                23       18                      
   ≥ 144                           24       13                      
  ALT (U/l)                                                         0.228 NS
   ≤ 32                            24       30                      
   \> 32 and \< 62                 24       17                      
   ≥ 62                            22       14                      
  Haemoglobin (g/dl)                                                0.125 NS
   ≤ 7.7                           23       16                      
   \> 7.7 and \< 10.0              22       22                      
   ≥ 10.0                          25       30                      
  Prothrombin time (s)                                              0.017
   ≤ 14                            23       34                      
   \> 14 and \< 40                 23       10                      
   ≥ 40                            23       22                      
  BUN (mg/dl)                                                       0.732 NS
   ≤ 16.1                          24       25                      
   \> 16.1 and \< 23.3             24       20                      
   ≥ 23.3                          22       25                      
  CRE (mg/dl)                                                       0.974 NS
   ≤ 0.8                           24       25                      
   \> 0.8 and \< 1.3               21       17                      
   ≥ 1.3                           25       18                      

CI -- confidence interval, TAE -- transcatheter arterial embolization, Cons T -- conservative treatment, NS -- not significant, HCC -- hepatocellular carcinoma, CI -- confident interval, AFP -- α-fetoprotein, AST -- aspartate aminotransferase, ALT -- alanine aminotransferase

![Cumulative survival rates in the conservative treatment (Cons T) group (*n* = 20) and in the transcatheter arterial embolization (TAE) group (*n* = 51). Difference between groups is not significant (*p* = 0.213)](PJR-83-77024-g001){#f0001}

A multivariable analysis admitted factors that were shown to be significant in the univariate analysis. Hepatic encephalopathy, serum total bilirubin, albumin, and prothrombin time were excluded from the analysis because they are included in the Child-Pugh classification. The multivariable analysis identified only the presence of distant metastasis as an independent factor determining lower overall survival (*p* = 0.023) ([Table 3](#t0003){ref-type="table"}, [Figure 2](#f0002){ref-type="fig"}).

###### 

Multivariable analysis searching for factors influencing overall survival

  Variables                                Hazard ratio   95% CI        *p* value
  ---------------------------------------- -------------- ------------- -----------
  Sex (female)                             1.967          0.889-4.355   0.095 NS
  Child-Pugh classification                                             
   C                                       2.208          0.574-8.491   0.249 NS
   B                                       1.282          0.361-4.548   0.700 NS
  Portal vein tumor thrombosis (present)   2.080          0.962-4.497   0.063 NS
  Distant metastasis (present)             2.313          1.123-4.767   0.023
  History of HCC treatment (present)       1.524          0.731-3.174   0.261 NS

CI -- confidence interval, NS -- not significant, HCC -- hepatocellular carcinoma

![Cumulative survival rates in the absence of distant metastasis group (*n* = 55) and in the presence group (*n* = 16). Overall survival rate is significantly higher in the absence group than in the presence group (*p* = 0.005)](PJR-83-77024-g002){#f0002}

We performed an additional subanalysis including 55 patients without distant metastasis. A multivariable analysis showed that the presence of portal vein tumour thrombosis was the only significant independent prognostic factor (*p* = 0.015) ([Table 4](#t0004){ref-type="table"}, [Figure 3](#f0003){ref-type="fig"}).

###### 

Multivariable analysis including patients without distant metastasis

  Variables                                 Hazard ratio   95% CI        *p* value
  ----------------------------------------- -------------- ------------- -----------
  Sex (female)                              2.249          0.894-5.657   0.085 NS
  Child-Pugh classification                                              
   C                                        1.849          0.368-9.283   0.455 NS
   B                                        1.379          0.303-6.260   0.678 NS
  Portal vein tumour thrombosis (present)   2.896          1.222-6.864   0.015
  History of HCC treatment (present)        1.482          0.616-3.564   0.380 NS

CI -- confidence interval, NS -- not significant, HCC -- hepatocellular carcinoma

![Cumulative survival rates in the absence of portal vein tumor thrombosis group (*n* = 42) and in the presence group (*n* = 13) without distant metastasis. Overall survival rate is significantly higher in the absence group than in the presence group (*p* \< 0.001)](PJR-83-77024-g003){#f0003}

Discussion {#sec4}
==========

In the past, patients with spontaneously ruptured HCC were treated by various surgical procedures including perihepatic packing, suture plication of bleeding tumour, injection of absolute alcohol, hepatic artery ligation, and liver resection \[[@cit0002]-[@cit0013]\]. However, because those patients tend to have advanced disease and poor liver function from cirrhosis, invasive surgical interventions may not be tolerated. Thus, less invasive treatments such as TAE or conservative management are chosen in the majority of cases. TAE is considered to be highly effective in controlling haemorrhage due to ruptured HCC, and we expected that it would improve prognosis of the affected patients compared to conservative treatment. In fact, our results showed a better prognosis in the TAE group (MST = 28 days) than in the Cons T group (MST = 16 days), but no significant difference in overall survival was revealed between the two groups (*p* = 0.213). An earlier retrospective study reported by Kirikoshi *et al*. showed a significantly better prognosis in patients treated with TAE (MST = 224.8 days) than in those treated with conservative therapy (MST = 13.1 days) \[[@cit0011]\]. The discrepant results can possibly be accounted for by relatively better liver function in their patients than those in our study: percentage of child A patients was 24% and the mean of total bilirubin was 1.8 mmol/l in their study, while percentage of child A patients was 11% and the mean total bilirubin was 3.4 mmol/l in our study.

Despite a multitude of previous studies, no general consensus has been achieved on prognostic factors in patients with spontaneous rupture of HCC. In our multivariable analysis, the presence of distant metastasis was the only significant factor that was associated with lower overall survival ([Table 3](#t0003){ref-type="table"}, [Figure 2](#f0002){ref-type="fig"}). Sixteen patients had distant metastasis (lung in 11 cases, lymph node in two cases, peritoneum in one case, adrenal gland in one case, and bone in one case), and their MST was 10 days (22 days in the absence group). Aoki *et al*. \[[@cit0006]\] analysed patients with spontaneous rupture of HCC and reported that stage IV group was associated with worse prognosis than the stage I-III group. Ueno *et al*. \[[@cit0014]\] reported that extrahepatic metastasis showed prognostic significance in multivariate analysis of unresectable HCC patients treated with transcatheter arterial chemoembolisation therapy. Distant metastasis of HCC has been regarded as a terminal event, and intrahepatic lesions were not actively treated in such cases \[[@cit0015]\]. However, some pervious reports showed that the metastatic lesion of HCC was a minor cause of death and the main cause of death was advanced intrahepatic lesions. In those reports, it was said that if a patient's liver status is good, treatment for liver and metastatic lesion may improve survival \[[@cit0016]-[@cit0019]\]. In general, ruptured HCC patient's liver status was mostly not good. In cases where distant metastasis is present, one should be careful about introducing TAE for treatment of ruptured HCC. Conservative treatment may be preferred in such cases.

Our univariate analysis revealed several additional items as possible prognostic factors. The presence of portal vein tumour thrombosis was significantly associated with lower overall survival ([Table 2](#t0002){ref-type="table"}). MST of 19 patients with portal vein tumour thrombosis was 10 days while that of the absence group was 29 days. Okazaki *et al*. performed TAE in 38 patients with ruptured HCC. Although patients without portal vein tumour thrombus showed longer MST (133 days) than those with it (90 days), no significant difference in prognosis was demonstrated \[[@cit0013]\]. Nevertheless, our subanalysis including patients without distant metastasis (*n* = 55) identified it as an independent prognostic factor (*p* = 0.015) ([Table 4](#t0004){ref-type="table"}, [Figure 3](#f0003){ref-type="fig"}). Thus, we consider that portal vein tumour thrombus could be a prognostic factor of ruptured HCC. Portal vein tumour thrombus was found in 12-39% of patients with HCC \[[@cit0001],[@cit0020]-[@cit0022]\] and 18-57% of patient with ruptured HCC \[[@cit0006],[@cit0012],[@cit0013]\]. Yamada *et al*. \[[@cit0023]\] reported that TAE was contraindicated for patients with portal vein tumour thrombus, because TAE might increase the risk of ischaemic liver damage. On the other hand, some groups reported that TAE was a safe treatment method of HCC with peripheral portal vein tumour thrombus if the patient has good liver function \[[@cit0024]-[@cit0027]\]. In our study, 19 patients (26%) had portal vein tumour thrombus, and TAE was conducted in 12 cases. There was no significant difference in the survival rate between TAE and conservative treatment (*p* = 0.1329). When central portal vein tumour thrombus is present, patients with ruptured HCC should be treated conservatively.

Tarantino *et al*. \[[@cit0005]\] reported that Child-Pugh A vs. B/C variables were statistically significant for overall survival of ruptured HCC patients. In agreement with their report, there was a significant difference in overall survival by Child-Pugh classification factor (C \> A) in our univariate analysis ([Table 2](#t0002){ref-type="table"}), although significant association was not confirmed in the multivariable analysis. This could be partly due to the small number of patients in the Child-Pugh A group (*n* = 8).

The presence of hepatic encephalopathy, which is one of the criteria of Child-Pugh classification, was associated with lower overall survival in our univariate analysis ([Table 2](#t0002){ref-type="table"}). Five patients had hepatic encephalopathy, and their MST was one day, whereas MST of 64 patients without it was 25 days. Kim *et al*. \[[@cit0007]\] studied 62 patients with ruptured HCC and found that early deaths were independently associated with the presence of hepatic encephalopathy.

Serum levels of albumin and total bilirubin are also included in the criteria of Child-Pugh classification. In the univariate analysis, lower albumin and higher bilirubin levels were found to be significantly associated with worse prognosis in ruptured HCC ([Table 2](#t0002){ref-type="table"}). Okazaki *et al*. \[[@cit0013]\] reported that MST of the lower serum bilirubin value group (≤ 3.0 mg/dl) was 165 days and that of the higher value group (\> 3.0 mg/dl) was 13 days, and that there was significant difference in the survival rate between lower and higher value groups. In our study, MST of the lower serum bilirubin value group (≤ 3.0 µmol/l) was 25 days and that of the higher serum bilirubin value group (\> 3.0 µmol/l) was 14 days.

There were some limitations in our study. Selection bias may exist due to the retrospective nature of this study. The Cons T group was relatively small.

Conclusions {#sec5}
===========

The presence/absence of distant metastasis appears to be a prognostic factor in spontaneous rupture of HCC. In cases of absent metastasis, portal vein tumour thrombosis could influence the prognosis. Although TAE was associated with longer survival than conservative treatment, our data failed to provide evidence of a significant impact of TAE as the primary management of ruptured HCC. TAE should be conducted with caution, especially in patients with advanced disease.
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